Implementation of EHR not linked to outcomes for heart failure patients

A hospital’s degree of electronic health record (EHR) implementation was not associated with improved outcomes in heart failure (HF) patients, according to a study published March 30 in the Journal of the American Heart Association.

In this study, researchers examined 2008 data from the Get With The Guidelines—HF Registry to determine what effect EHRs had on quality of care and patient outcomes.

“Heart failure is the most common admission diagnosis among Medicare recipients, and readmission rates unfortunately remain high,” wrote first author Senthil Selvaraj and colleagues. “The approach to reduce HF disease burden has been multifaceted, and use of the EHR may improve the HF morbidity and mortality through improved quality of care. Whether these theoretic benefits translate into actual improvements in patient care is of vital interest from clinical, economic, and policy perspectives.”

Overall, 21,222 patients were analyzed for the study—1,484 patients were in a hospital with no EHR, 13,473 in a hospital with partial EHR and 6,265 in a full EHR hospital. Factors of 30‐day mortality, readmission and a composite outcome were evaluated in relation to EHR states.

Results showed no association between the degree of EHR implementation and quality or in-hospital outcomes.

“EHR is a tool in increasingly complex hospital infrastructures, and recent studies have shown that providers spend a substantial amount of daily workflow interacting with a more contemporary form of the EHR than studied herein,” concluded Selvaraj and colleagues. “Our findings underscore the need for improved use of EHR or refinement of its clinical decision support and algorithm construction.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.